UBQLN1 Inhibition reduces MASH progression through downregulating SIKE/p38 MAPK pathway in hepatocyte
These findings establish the UBQLN1-SIKE-p38 MAPK axis as a critical regulatory pathway in MASH pathogenesis and develop an RBC-EVs-targeted delivery system for MASH therapy.
Authors
- L.-P. Liu
- Guojun Zheng (ORCID: https://orcid.org/0009-0000-8186-7359)
- Fan Yang (ORCID: https://orcid.org/0000-0001-6790-8361)
- Yushan Yan (ORCID: https://orcid.org/0000-0001-6616-4575)
- Yifei Chen
- Yanjin Wang
Institutions
- Jiangsu University (CN)
- Xuzhou Medical College (CN)
- Changzhou Third People's Hospital (CN)
Publication Details
- Journal
- Journal of Nanobiotechnology
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1186/s12951-026-04202-x
- Primary Topic
- NF-κB Signaling Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00